Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Oct 3 - Oct 8
The differentiating case for berobenatide rests primarily on dosing convenience: a once-monthly injection could meaningfully improve real-world adherence for a condition that requires indefinite treatment
Its main actions include: Stimulating insulin secretion from pancreatic beta cells in a glucose-dependent manner Suppressing glucagon release, which reduces hepatic glucose production Slowing gastric emptying, which moderates post-meal glucose spikes Promoting satiety through central nervous system pathways, thereby reducing appetite GIP is released by K-cells in the proximal small intestine and shares some functions with GLP-1, particularly in enhancing insulin secretion after meals
Additionally, the long-term (3-month) safety of the optimized SSPH-MPN was evaluated
Studies show maximum ALT reduction occurs around 30 weeks of GLP-1 treatment
US$ 27.74
US$ 20.31
US$ 23.16
US$ 22.34
